Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Combination therapy with pegylated interferon-alpha plus ribavirin has greatly improved the
treatment efficacy and is the mainstream of treatment for chronic hepatitis C infection. The
efficacy and safety of pegylated interferon-alpha plus ribavirin combination therapy and its
impact on the outcome in chronic hepatitis C patients concomitant with malignancy other than
hepatocellular carcinoma deserve to be elucidated.
The purposes of this study are:
1. To evaluate the efficacy and safety of pegylated interferon-alpha 2a plus ribavirin
combination therapy in chronic hepatitis C patients concomitant with malignancy other
than hepatocellular carcinoma, compare to those without systemic malignancy.
2. To investigate the role of baseline and on-treatment factors on the response to
pegylated interferon-alpha 2a plus ribavirin combination therapy in chronic hepatitis C
patients concomitant with malignancy other than hepatocellular carcinoma.
Phase:
Phase 4
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital